Anixa Biosciences is trading at $3.14 (7.6% down) in after-hours, reversing its 5.1% regular-session rebound as the broader biotech sector remains under pressure.
- The move appears tied to risk-off sentiment following a volatile week for growth and healthcare names, rather than company-specific news.
- No fresh catalysts or earnings releases were reported by the company to account for the after-hours decline.
- The drop effectively erases the gains made during the regular trading session as sector-wide headwinds persist.